Atherosclerosis: Successes, Surprises, and Future Challenges

Circulation Research

Volumn 118, Issue 4, 2016, Pages 531-534

  Libby, Peter ^a   Bornfeldt, Karin E ^b,c   Tall, Alan R ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

atherosclerosis; clinical trial; Editorials; endothelial cells; epidemiology; leukocytes; pharmacology; smooth muscle cells; vascular cell biology

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MICRORNA; SMALL UNTRANSLATED RNA; TRIACYLGLYCEROL; BIOLOGICAL MARKER; LIPID;

ADAPTIVE IMMUNITY; ANGIOCARDIOGRAPHY; APOPTOSIS; ATHEROGENESIS; AUTOIMMUNE DISEASE; BONE MARROW CELL; CARDIOVASCULAR RISK; CELL FATE; CELL FUNCTION; CELL LEVEL; CELL MEMBRANE; CELL POPULATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; CORONARY ARTERY ATHEROSCLEROSIS; CYTOLOGY; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME REGULATION; EPIDEMIC; EPIDEMIOLOGY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; GOLD STANDARD; HEMATOPOIETIC STEM CELL; HEREDITY; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTOSIS; LIPID METABOLISM; MACROPHAGE FUNCTION; MENDELIAN RANDOMIZATION ANALYSIS; MICROENVIRONMENT; MONOCYTE; MONONUCLEAR CELL; MONONUCLEAR PHAGOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENESCENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; T LYMPHOCYTE ACTIVATION; THROMBOSIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ATHEROSCLEROSIS; BLOOD; PROGNOSIS; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; BIOMARKERS; HUMANS; LIPIDS; PROGNOSIS; RISK FACTORS;

EID: 84959062601     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308334     Document Type: Editorial

References (30)

1. Brown MS, Goldstein JL., Heart attacks: gone with the century? Science 1996 272 629
2. Mozaffarian D, Benjamin EJ, Go AS, Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016 133 e38 e360. doi: 10.1161/CIR.0000000000000350.
3. Murray CJ, Vos T, Lozano R, Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 380 2197 2223. doi: 10.1016/S0140-6736(12)61689-4.
4. Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S., Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 2016 118 535 546. doi: 10.1161/CIRCRESAHA.115.307611.
5. Wallentin L, Becker RC, Budaj A, PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 361 1045 1057. doi: 10.1056/NEJMoa0904327.
6. Mega JL, Braunwald E, Wiviott SD, ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012 366 9 19. doi: 10.1056/NEJMoa1112277.
7. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M., Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015 36 1163 1170. doi: 10.1093/eurheartj/ehu505.
8. Nordestgaard BG., Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 2016 118 547 563. doi: 10.1161/CIRCRESAHA.115.306249.
9. Morgan TM, Krumholz HM, Lifton RP, Spertus JA., Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007 297 1551 1561. doi: 10.1001/jama.297.14.1551.
10. McPherson R, Tybjaerg-Hansen A., Genetics of coronary artery disease. Circ Res 2016 118 564 578. doi: 10.1161/CIRCRESAHA.115.306566.
11. Musunuru K, Kathiresan S., Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res 2016 118 579 585. doi: 10.1161/CIRCRESAHA.115.306398.
12. Nurnberg S, Zhang H, Hand N, Bauer R, Saleheen D, Rader D, Reilly M., From loci to biology: functional genomics of genome-wide association for coronary disease. Circ Res 2016 118 586 606. doi: 10.1161/CIRCRESAHA.115.306464.
13. Mega JL, Stitziel NO, Smith JG, Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015 385 2264 2271. doi: 10.1016/S0140-6736(14)61730-X.
14. Paynter NP, Ridker PM, Chasman DI., Are genetic tests for atherosclerosis ready for routine clinical use? Circ Res 2016 118 607 619. doi: 10.1161/CIRCRESAHA.115.306360.
15. Gimbrone MA Jr, Garcia-Cardena G., Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016 118 620 636. doi: 10.1161/CIRCRESAHA.115.306301.
16. Cybulsky MI, Cheong C, Robbins CS., Macrophages and dendritic cells: partners in atherogenesis. Circ Res 2016 118 637 652. doi: 10.1161/CIRCRESAHA.115.306542.
17. Tabas I, Bornfeldt KE., Macrophage phenotype and function in different stages of atherosclerosis. Circ Res 2016 118 653 667. doi: 10.1161/CIRCRESAHA.115.306256.
18. Ketelhuth DFJ, Hansson GK., Adaptive response of T and B cells in atherosclerosis. Circ Res 2016 118 668 678. doi: 10.1161/CIRCRESAHA.115.306427.
19. Sorci-Thomas MG, Thomas MJ., Microdomains, inflammation, and atherosclerosis. Circ Res 2016 118 679 691. doi: 10.1161/CIRCRESAHA.115.306246.
20. Bennett MR, Sinha S, Owens GK., Vascular smooth muscle cells in atherosclerosis. Circ Res 2016 118 692 702. doi: 10.1161/CIRCRESAHA.115.306361.
21. Benditt EP., Evidence for a monoclonal origin of human atherosclerotic plaques and some implications. Circulation 1974 50 650 652
22. Ross R, Glomset JA., The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976 295 369 377. doi: 10.1056/NEJM197608122950707.
23. Ross R, Glomset JA., The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976 295 420 425. doi: 10.1056/NEJM197608192950805.
24. Feinberg MW, Moore KJ., MicroRNA regulation of atherosclerosis. Circ Res 2016 118 703 720. doi: 10.1161/CIRCRESAHA.115.306300.
25. Pedersen TR., The success story of LDL cholesterol lowering. Circ Res 2016 118 721 731. doi: 10.1161/CIRCRESAHA.115.306297.
26. Shapiro MD, Fazio S., From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res 2016 118 732 749. doi: 10.1161/CIRCRESAHA.115.306471.
27. Tarkin JM, Dweck MR, Evans NR, Takx RAP, Brown AJ, Tawakol A, Fayad ZA, Rudd JHF., Imaging atherosclerosis. Circ Res 2016 118 750 769. doi: 10.1161/CIRCRESAHA.115.306247.
28. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T, CANTOS Pilot Investigative Group Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012 126 2739 2748. doi: 10.1161/CIRCULATIONAHA.112.122556.
29. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM., Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013 166 199 207.e15. doi: 10.1016/j.ahj.2013.03.018.
30. Libby P, Tabas I, Fredman G, Fisher EA., Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014 114 1867 1879. doi: 10.1161/CIRCRESAHA.114.302699.